2. シグナル伝達
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC 関連カスタムサービス

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
製品番号 製品名 製品効果 純度 構造式
  • HY-136315
    OSu-Glu-VC-PAB-MMAD
    OSu-Glu-VC-PAB-MMAD is a agent-linker conjugate for ADC with potent antitumor activity by using MMAD (a potent tubulin inhibitor), linked via the cleavable ADC linker OSu-Glu-VC-PAB.
    OSu-Glu-VC-PAB-MMAD
  • HY-177686
    N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(Azido-PEG4)-N-(PEG4-Val-Cit-PAB-MMAF)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-153909
    SMP-33693
    SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
    SMP-33693
  • HY-148399
    Mal-VC-PAB-PNP-CDN-A
    Mal-VC-PAB-PNP-CDN-A is a drug-Linker conjugates for ADC.
    Mal-VC-PAB-PNP-CDN-A
  • HY-177548
    Fmoc-Val-Cit-PAB-Exatecan
    Fmoc-Val-Cit-PAB-Exatecan is a Drug-linker conjugate for ADC. Fmoc-Val-Cit-PAB-Exatecan contains the ADC linker (Fmoc-Val-Cit-PAB) and a DNA topoisomerase I inhibitor Exatecan (HY-13631).
    Fmoc-Val-Cit-PAB-Exatecan
  • HY-181958
    mAb-AsnAsn-E104
    mAb-AsnAsn-E104 is a conjugate of an ADC drug toxin molecule and a linker, which contains a degradable PEG linker and the toxin molecule E104 (HY-156174).
    mAb-AsnAsn-E104
  • HY-148067A
    XMT-1519 conjugate-1 TFA
    XMT-1519 conjugate-1 TFA (compound 31) is part of the drug-linker conjugate for ADC and can be conjugated with the HER-2 monoclonal antibody Calotatug (XMT-1519) (HY-P990909) for the synthesis of ADC.
    XMT-1519 conjugate-1 TFA
  • HY-177685
    N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(TCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-181992
    Mal-PEG4-Val-Cit-PAB-MSA-2
    Mal-PEG4-Val-Cit-PAB-MSA-2 is a Drug-Linker Conjugates for ADC. Mal-PEG4-Val-Cit-PAB-MSA-2 consists of the ADC Cytotoxin MSA-2 (HY-136927) and a linker Mal-PEG4-Val-Cit-PAB-OH (HY-140143). Mal-PEG4-Val-Cit-PAB-MSA-2 can be used for synthesis of ADCs.
    Mal-PEG4-Val-Cit-PAB-MSA-2
  • HY-181428
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel (compound 16h-3) is a drug-linker conjugate for ADC, which comprises a microtubule depolymerization inhibitor and a linker. Puxitatug samrotecan drug-linker can be used to synthesize antibody-drug conjugate (ADC).
    Fmoc-Gly-Gly-Phe-Gly-Docetaxel
  • HY-175272
    DBCO-PEG8-VKG-CPT2
    DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162) and a stable and cleavable linker (DBCO-PEG8-VKG) (HY-175426). DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs.
    DBCO-PEG8-VKG-CPT2
  • HY-185493
    Mal-VC-PAB-seco-CBI-PBD dimer
    Mal-VC-PAB-seco-CBI-PBD dimer is a highly active drug-linker conjugate. Mal-VC-PAB-seco-CBI-PBD dimer integrates the DNA-damaging effects of two distinct types of compounds: seco-cyclopropabenzindoline (seco-CBI) and pyrrolobenzodiazepine (PBD). Mal-VC-PAB-seco-CBI-PBD dimer is linked via a valine-alanine (VC) linker cleavable by cathepsin B and achieves targeted delivery relying on monoclonal antibodies. Mal-VC-PAB-seco-CBI-PBD dimer is applicable for cancer research.
    Mal-VC-PAB-seco-CBI-PBD dimer
  • HY-144497
    HE-S2
    HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity.
    HE-S2
  • HY-128952G
    Tesirine (GMP)
    Tesirine (GMP) (SG3249 (GMP)) is Tesirine (HY-128952) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity.
    Tesirine (GMP)
  • HY-175884
    TUB-010 drug-linker
    TUB-010 drug-linker is a drug-linker conjugate for ADC, which comprises a mitotic inhibitor MMAE (HY-15162 )and a linker. TUB-010 drug-linker can be used for synthesis of ADC TUB-010.
    TUB-010 drug-linker
  • HY-164705
    Mal-Toxophore
    Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759).
    Mal-Toxophore
  • HY-177679
    N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(Amino-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-128894
    MC-Sq-Cit-PAB-Dolastatin10
    MC-Sq-Cit-PAB-Dolastatin10 is a agent-linker conjugate for ADC with potent antitumor activity by using Dolastatin10 (a tubulin polymerization inhibitor), linked via the ADC linker MC-Sq-Cit-PAB.
    MC-Sq-Cit-PAB-Dolastatin10
  • HY-112805
    ST8154AA1
    ST8154AA1 is a part of antibody agent conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity.
    ST8154AA1
  • HY-144629
    Asn-Pro-Val-PABC-MMAE TFA
    Asn-Pro-Val-PABC-MMAE TFA (compound 8) is a potent ADC Linker used in the synthesis of antibody-drug conjugates (ADCs).
    Asn-Pro-Val-PABC-MMAE TFA
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.